Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Iron chelation therapy in myelodysplastic syndromes.

    ... requires treatment. Supportive care measures such as red blood cell transfusions and erythroid colony stimulating factors are ...

    Research Article last updated 07/20/2018 - 5:14pm.

  2. Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.

    ... 24 and 52 weeks of therapy despite ongoing receipt of red blood cell transfusions. ...

    Research Article last updated 07/20/2018 - 5:14pm.

  3. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.

    ... myelodysplastic syndromes (MDS) treated with red blood cell (RBC) transfusions. Transfusion dependency is associated with ...

    Research Article last updated 07/20/2018 - 5:14pm.

  4. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study

    ... mg at 16 weeks, respectively. RESULTS: Rates of red blood cell - transfusion independence (RBC-TI) ≥182 days were ...

    Research Article last updated 07/20/2018 - 5:15pm.

  5. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab

    ... Journal Title:  Blood Primary Author:  ... During the study, six patients received at least one red blood cell transfusion . Lack of detectable CH50 activity (defined by ...

    Research Article last updated 07/20/2018 - 5:15pm.

  6. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

    ... Journal Title:  Blood Primary Author:  ... cytogenetics , presence of circulating blasts, and red blood cell transfusion dependency ≥ 4 units/8 weeks (all P < 10(-4)) ...

    Research Article last updated 07/20/2018 - 5:14pm.

  7. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

    ... Overall Response (complete or partial remission, red blood cell [RBC] or platelet transfusion independence [TI], or ...

    Research Article last updated 07/20/2018 - 5:15pm.

  8. Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes

    ... catheter placement (ORadj=6.47, 95% CI: 2.37, 17.62) and red blood cell transfusion (ORadj=4.60, 95% CI: 2.29, 9.23) were associated ...

    Research Article last updated 07/20/2018 - 5:14pm.

  9. A novel marker for screening paroxysmal nocturnal hemoglobinuria using routine complete blood count and cell population data

    ... marker. METHODS: We analyzed 979 complete blood counts (CBC) data from 963 patients including 57 data from 44 PNH ... were followed: flow cytometry for CD55 and CD59 on red blood cells (RBCs) to a detection level of 1%; and fluorescent aerolysin, ...

    Research Article last updated 07/20/2018 - 5:15pm.

  10. Late Effects in Hematopoietic Cell Transplant Recipients with Acquired Severe Aplastic Anemia: A Report from the Late Effects Working Committee of the Center for International Blood and Marrow Transplant Research

    ... Journal Title:  Biol Blood Marrow Transplant Primary ... HM, Mehta P, Myers KC, Parsons SK, Passweg JR, Pidala J, Red Original Publication Date:  ...

    Research Article last updated 07/20/2018 - 5:14pm.